Trade War

Five months on, the US case against German drug prices has no ruling and no tariff

Washington opened a Section 301 investigation in June into what it calls Germany's underpayment for new medicines. A hearing was set for 22 September. Berlin rejects the charge, has passed its savings law, and is reported to be in talks.

US tariffs 17 November 2026

The United States has not announced a finding in the investigation it opened on 18 June 2026 into the prices Germany pays for new medicines. The case is the first use of Section 301 against another country's drug-pricing system, and it could end in tariffs on German goods. The latest dated developments this site could confirm are the public hearing set for 22 September, a German press report of 29 September that officials from both governments were in talks, and a German think-tank paper of 14 October advising Berlin not to sign the kind of deal Washington wants.1 4 5

What Washington alleges

Section 301 of the Trade Act of 1974 lets the US Trade Representative investigate a foreign government's practices and, if it finds them unreasonable or discriminatory and a burden on American commerce, respond with tariffs or other measures. The notice opening this case says Germany holds the prices of patented medicines below fair market value, so that American patients pay a disproportionate share of the world's research costs. It says US consumers pay about 3.9 times what German consumers pay for brand-name drugs.1

The notice names two German practices to begin with:

The Trade Representative, Jamieson Greer, said when he opened the case that he was "particularly concerned" that Germany was fast-tracking that law, and called it "a serious step backwards". He pointed to an arrangement on drug prices that the United States and Britain announced on 2 April 2026 and said Germany "should follow suit with constructive negotiations". Washington also asked Berlin for formal consultations.2

What has happened since

Written comments were due by 10 August and the hearing before the inter-agency Section 301 Committee was set for 22 September at the US International Trade Commission, with rebuttal comments due seven days after it ended. The notice sets no date for a decision. If the finding goes against Germany, the Trade Representative must then decide whether to act and how; the notice asked the public to comment on "tariff and non-tariff actions".1

Germany passed the law regardless. According to the German Institute for International and Security Affairs (SWP), a Berlin think tank, the law to stabilise health-insurance contributions was adopted in July 2026 and raises the compulsory manufacturer rebate from 7% to 15.5%, probably from January 2027. German press reports from June said the aim was to close a shortfall of about €20 billion in the statutory health insurers' finances.4 3

Berlin's position

The German government says drug reimbursement is a national matter and asks Washington to keep to the tariff agreements already made. A German press report of 20 June gave that as Chancellor Merz's answer, and said the economy ministry was seeking dialogue. The health minister, Ms Warken, pointed to the strained finances of the insurers.3

The trade paper Pharmazeutische Zeitung reported on 29 September, drawing on the weekly Wirtschaftswoche, that the government does not accept the charge because Germany has the highest medicine prices in the European Union, and that officials from the health and economy ministries were in compromise talks with Washington. It quoted Matthias Mieves, a health-policy politician of the Social Democratic Party (SPD):5

Die Realität ist, dass die Arzneimittelpreise in den Vereinigten Staaten viel zu hoch sind.

The reality is that medicine prices in the United States are far too high.5

The same report said Bernd Lange, who chairs the European Parliament's trade committee, backed Germany and warned against single EU states making their own trade arrangements with the United States. The paper notes that trade policy lies with the European Commission.5

What German analysts advise

The SWP paper of 14 October puts the stakes plainly:4

Die Untersuchung könnte letztlich zur Verhängung von Zöllen gegen Deutschland führen.

The investigation could ultimately lead to the imposition of tariffs on Germany.4

Its authors call the case a first, because Washington is questioning another country's whole method of setting drug prices. They refer to recent reports of talks between German and American officials on a bilateral agreement and advise Germany to refuse one on the British model. They suggest the European Commission examine whether the American step counts as economic coercion under the EU's anti-coercion regulation, a tool they say is meant to deter and not to retaliate. They also consider the American argument too simple, since high US prices have several causes.4

Where tariffs already stand

Medicines are already subject to a separate US tariff. The SWP paper notes that an April 2026 proclamation under Section 232, the national-security tariff power, set 100% on patented medicines, with 15% for EU products and 0% for companies that sign pricing and production agreements with Washington; it counts 26 companies that have done so. A Section 301 action against Germany would be a different measure, aimed at one country, and the notice does not say which goods any tariff would cover.4 1

Industry reactions differ in the reports read here. German press said the chemical industry association VCI called the American step protectionist, while Pfizer's chief executive said the German law endangered the predictability of investment.3

No determination, proposed action or agreement had been published in the sources read by 17 November 2026. The open questions are whether the reported talks produce an arrangement before Washington rules, and whether the higher German rebate takes effect in January 2027 as planned.4 5

Sources

  1. Office of the United States Trade Representative. Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany's Persistent Underpayment for Innovative Pharmaceutical Products (Federal Register notice, dockets USTR-2026-0463 and USTR-2026-0464). 18 June 2026United States' camp · government
  2. Office of the United States Trade Representative. USTR Announces Initiation of Section 301 Investigation of Germany's Persistent Underpayment for Innovative Pharmaceutical Products. 18 June 2026United States' camp · government
  3. ad-hoc-news.de. Arzneimittelpreise: USA leitet Untersuchung gegen deutsche Regulierung ein [Medicine prices: US opens investigation into German regulation]. 20 June 2026Germany's camp · press · in German
  4. Stiftung Wissenschaft und Politik (German Institute for International and Security Affairs). Arzneimittelpreise in Deutschland im Visier der USA, SWP-Aktuell 2026/A 51 [Medicine prices in Germany in the sights of the United States]. 14 October 2026Germany's camp · think tank · in German
  5. Pharmazeutische Zeitung. Zu billig für die USA? [Too cheap for the United States?]. 29 September 2026Germany's camp · trade press · in German

All articles